With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

Pfizer (NYSE: PFE) stock jumped 3.1% through 11:20 a.m. ET Monday morning in response to a Wall Street Journal article over ...

As you are likely aware, many people are using a class of drugs called GLP-1 receptor agonists for weight loss. One of the ...

In phase 2, VK2735 reduced patients' weight by about 15% after 13 weeks of treatment and maintained a clean safety profile.

Medifast, Inc. MED is making significant strides in adapting to the evolving healthcare landscape with the growing ...

Whilst it can work as an affective weight-loss drug for those who are obese, it should never be used for a short-term ...

The drug, initially intended for use by diabetics, has soared in popularity as a result of the weight-loss effects.

Scholar Rock is also working on a treatment that helps preserve lean muscle that is often lost during rapid weight loss by patients taking the new class of GLP-1 drugs. Scholar Rock's stock is down 45 ...

"It's very, very clear that physician spending is not the problem in healthcare." -- Jen Brull, MD, president of the American ...

Pfizer Inc (NYSE:PFE) shares are on the move Monday after activist Starboard Value acquired a $1 billion stake in the pharmaceutical giant. What Happened: Activist investor Starboard Value has taken a ...

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...